Company profile: Dermira
1.1 - Company Overview
Company description
- Provider of specialty biopharmaceutical development and commercialization of innovative dermatology therapies. Focused on bringing differentiated products to dermatologists and patients, with a portfolio of five product candidates. Founded in 2010, headquartered in Menlo Park, California.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Dermira
Asher Bio
HQ: United States
Website
- Description: Provider of cis-targeted cytokine immunotherapies that selectively activate CD8+ T cells for cancer and chronic viral infections. Pipeline includes AB248, a cis-targeted IL-2 in Phase 1a/1b for solid tumors; AB821, a CD8-targeted IL-21; AB359 for chronic viral infections including HBV; and cis-targeted cytokines to enhance CAR-T and other cell therapies by improving engraftment, persistence, and function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Asher Bio company profile →
Tectonic Therapeutics
HQ: United States
Website
- Description: Provider of GPCR-targeted biologic drug discovery and development via its GEODe platform, with clinical programs including TX45, a therapeutic protein in Phase 1B trials for Group 2 Pulmonary Hypertension in heart failure with preserved ejection fraction, and an Fc-relaxin fusion targeting the RXFP1 receptor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tectonic Therapeutics company profile →
Achilles Therapeutics
HQ: United Kingdom
Website
- Description: Provider of patient-specific cancer immunotherapies that harness the immune system to target truncal tumor neoantigens. Offers PELEUS, an AI-powered bioinformatics platform to identify clonal neoantigens; VELOS, a manufacturing process to create clonal neoantigen-reactive T cell (cNeT) products; and cNeT cell therapies targeting multiple clonal neoantigens to treat cancer while sparing healthy tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achilles Therapeutics company profile →
Kedrion Biopharma
HQ: United States
Website
- Description: Provider of plasma-derived medicinal products—clotting factors, albumin, and immunoglobulins—for treating hemophilia and immune deficiencies. Offers contract fractionation/manufacturing, technology transfer to build local plasma collection and fractionation, BioSC virus/prion safety studies (PCR, contaminants in cell cultures, in vitro, protein characterization), and pharmacovigilance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kedrion Biopharma company profile →
Tiziana Life Sciences
HQ: United Kingdom
Website
- Description: Provider of biotechnology therapies focused on discovery and development of novel molecules in oncology and immunology, including Intranasal Foralumab (anti-CD3 nasal immunotherapy for neuroinflammatory and neurodegenerative diseases), Anti IL-6R mAb (TZLS-501) to reduce inflammation in idiopathic pulmonary fibrosis and autoimmune diseases, and Milciclib, a CDK-targeting cancer therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tiziana Life Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Dermira
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Dermira
2.2 - Growth funds investing in similar companies to Dermira
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Dermira
4.2 - Public trading comparable groups for Dermira
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →